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SRp38 is an atypical SR protein splicing regulator.
To define the functions of SRp38 in vivo, we gener-
ated SRp38 null mice. The majority of homozygous
mutants survived only until E15.5 and displayed
multiple cardiac defects. Evaluation of gene expres-
sion profiles in the SRp38/ embryonic heart
revealed a defect in processing of the pre-mRNA
encoding cardiac triadin, a protein that functions in
regulation of Ca2+ release from the sarcoplasmic
reticulum during excitation-contraction coupling.
This defect resulted in significantly reduced levels
of triadin, as well as those of the interacting protein
calsequestrin 2. Purified SRp38 was shown to bind
specifically to the regulated exon and to modulate
triadin splicing in vitro. Extending these results,
isolated SRp38/ embryonic cardiomyocytes dis-
played defects in Ca2+ handling compared with
wild-type controls. Taken together, our results
demonstrate that SRp38 regulates cardiac-specific
alternative splicing of triadin pre-mRNA and, reflect-
ing this, is essential for proper Ca2+ handling during
embryonic heart development.
INTRODUCTION
Alternative splicing of mRNA precursors plays a major role in
expanding proteomic complexity and contributes significantly
to cell- and tissue-specific gene expression according to cell
type and developmental stage (Black, 2000; Blencowe, 2006).
Splicing decisions that determine the expression patterns of
different protein isoforms can have dramatic developmental
consequences (Hammes et al., 2001), and defects in the splicing
pathway have been shown to be associated with a variety of
human diseases (Wang and Cooper, 2007). These observations
indicate that understanding the mechanisms that control splice
site selection is of vital importance.
Splicing is carried out in the spliceosome, a macromolecular
complex containing five small nuclear ribonucleoprotein parti-
cles and a large number of auxiliary proteins (Jurica and Moore,528 Developmental Cell 16, 528–538, April 21, 2009 ª2009 Elsevier I2003; Konarska and Query, 2005). Among the best-character-
ized non-snRNP proteins are the serine/arginine (SR)-rich family
of splicing factors. SR proteins are highly conserved among
animals and plants and play key roles in both constitutive and
alternative splicing (Fu, 1995; Manley and Tacke, 1996; Grav-
eley, 2000; Black, 2003). All SR proteins contain one or two
RNP-type RNA-binding domains and an arginine-serine-rich
domain. Typical SR proteins affect splicing in two distinguish-
able ways: First, SR proteins play essential but redundant roles
in constitutive splicing, functioning as general splicing factors
in a manner that involves stabilizing the binding of snRNPs
to pre-mRNAs. Second, SR proteins bind in a sequence-specific
manner to exonic splicing enhancers to facilitate recruitment
of snRNPs to splice sites and thereby enhance exon inclusion.
Beyond its role in splicing, the function of SR proteins has more
recently been extended to mRNA export (Huang and Steitz,
2001), mRNA stability (Lemaire et al., 2002; Zhang and Krainer,
2004), genomic stability (Li and Manley, 2005), and translation
(Sanford et al., 2004), indicating that SR proteins are involved in
multiple cellular processes.
While SR proteins were discovered and characterized by
biochemical methods, genetic approaches have been employed
to address their physiological functions in living cells and organ-
isms. Inactivation of ASF/SF2 in chicken DT40 cells led to
general defects in RNA metabolism (Wang et al., 1996) and to
apoptotic cell death (Li et al., 2005). Deletion of SRp20 in mice
caused embryonic lethality at the blastocyst stage (Jumaa
et al., 1999). Similar early lethal phenotypes were also observed
in both SC35 (Wang et al., 2001) and ASF/SF2 (Xu et al., 2005)
knockout mice. These experiments suggested that SR proteins
perform fundamental functions crucial for cell viability. However,
heart-specific knockouts of either SC35 (Ding et al., 2004) or
ASF/SF2 (Xu et al., 2005) had little effect on cardiac develop-
ment, instead resulting in cardiomyopathy in adult mice. Interest-
ingly, only a specific set of alternative splicing events were
affected in the ASF/SF2-ablated hearts; expression of most
transcripts was unaltered (Xu et al., 2005). These findings point
to the possibility that SR proteins may act as specific splicing
regulators that play defined roles in specific cells and tissues.
SRp38 is an unusual member of the SR protein family.
Although structurally similar to typical SR proteins, SRp38 is
unable to activate splicing in standard in vitro assays, suggesting
that it cannot function as a general splicing activator (Shin andnc.
Developmental Cell
SRp38 Is Required for Proper Heart DevelopmentManley, 2002). Instead, SRp38 functions as a general splicing
repressor, but only when activated by dephosphorylation (Shin
and Manley, 2002). Another unusual property of SRp38 is that
loss of SRp38 does not affect cell viability, although a prolonged
G2/M phase and poor recovery following heat shock were
observed in SRp38/ DT40 cells (Shin et al., 2004). Recent
experiments have shown that, despite its inactivity as a general
splicing factor, phosphorylated SRp38 can function as a
sequence-dependent splicing activator (Feng et al., 2008).
In this report, we describe the generation and characterization
of SRp38/ mice. Consistent with the dispensability of SRp38
for cell viability, mice survive through early embryogenesis but
die progressively from mid-gestation until birth with multiple
cardiac defects. To investigate the possible molecular basis for
this, microarray analysis of RNA isolated from mutant and wild-
type embryonic ventricles was performed but revealed only
limited differences. Notably, however, the ratio of alternatively
spliced isoforms of the mRNA encoding the cardiac protein
triadin was significantly altered in mutant embryos, resulting in
significantly reduced levels of triadin as well as of the interacting
protein calsequestrin 2 (CSQ2). These proteins play a critical role
in excitation-contraction (EC) coupling, functioning in regulation
of Ca2+ release from the sarcoplasmic reticulum. By analyzing
RNA binding by purified SRp38 and alternative splicing of triadin
pre-mRNAs in cell extracts and stable transfection assays, we
demonstrate that SRp38 directly modulates triadin alternative
splicing. Importantly, using primary cultures of embryonic cardio-
myocytes and Ca2+ imaging, we observed abnormal Ca2+
release from the sarcoplasmic reticulum in the SRp38/
myocytes. The frequency of Ca2+ sparks was significantly
increased, while the spark amplitude was reduced. We conclude
that SRp38-regulated alternative splicing plays a critical role
during embryonic heart development.
RESULTS
Generation of SRp38-Deficient Mice
Our previous data have shown that SRp38 is not required for
viability of DT40 cells (Shin et al., 2004). Given this, we reasoned
that disruption of SRp38 in mice would not result in early embry-
onic lethality and might give rise to informative phenotypes. We
therefore set out to disrupt SRp38 in mice by a conventional
gene-targeting strategy (see Experimental Procedures). In brief,
a gene targeting vector was constructed (see Figure S1Amiddle,
Figure 1. TheMajority of SRp38/Mice Die
before Birth and Display Severe Edema
(A) Mutant mice that survive to term are severely
growth retarded and die within the first day.
(B) Severe edema is visible in the E14.5 SRp38/
embryo. The arrow indicates edema along the
back of the SRp38/ embryo.
available online) and electroporated into
E14 embryonic stem cells, and following
homologous recombination a neoR
cassette was introduced in an antisense
orientation to disrupt the gene near the
50 end (Figure S1A, bottom). Double-drug-resistant clones
were screened by Southern blotting using exon-specific and
neo-specific probes as indicated in Figure S1A (data not shown).
Two homologous recombinants were injected into C57BL/6J
blastocysts to produce male chimeras that transmitted the
mutated SRp38 allele through the germline to 50%of their agouti
129/C57BL/6 offspring. F1 SRp38+/ males and females were
then interbred to produce F2 litters. Genotypes were confirmed
by PCR analysis (Figure S1B) and Southern blot (Figure S1C).
The heterozygous mice appeared completely normal and
fertile. However, no homozygous mutant mice were identified
among 82 pups from heterozygous intercrosses, suggesting
that a lack of SRp38 results in embryonic lethality. Examination
of embryos at various times during gestation revealed that the
majority of SRp38/ embryos died before or around develop-
mental day E15.5, with only 5% (6 out of 110) surviving until
birth (Figure S1D). Genetic background had no apparent effect
on the phenotypes of the SRp38/ mice (data not shown).
SRp38/ Mice Display Multiple Cardiac Defects
We next examined morphological and histological properties of
the SRp38/ mice. The few mutant mice that survived to full
term were growth retarded and did not live through the first day
(Figure 1A). However, up until E12.5SRp38/, embryos showed
no apparentmorphological abnormalities (data not shown). From
E13.5 to E16.5, the SRp38/ embryos displayed noticeable
edema along the back as well as slight growth retardation, indic-
ative of severe cardiac defects (Figure 1B). Strikingly, despite the
fact that SRp38 is widely expressed (Shin and Manley, 2002),
other tissues and organs appeared normal.
To examine the cardiac defects of the SRp38 null embryos,
histological sections were generated from E14.5 and E16.5
wild-type and SRp38/ embryos (Figures 2A–2F). HE staining
(see Experimental Procedures) revealed severe morphological
abnormalities, including atrial septal defects (ASD) and ventri-
cular septal defects (VSD), in the E14.5 SRp38/ heart
(compare Figures 2A and 2B). High magnification further re-
vealed that the myocardium was thin, undifferentiated, and
arranged in a disorganized manner, in contrast to that in
wild-type hearts (compare Figures 2C and 2D). Moreover, an
atrioventricular canal defect (AVCD) was detected in the E16.5
mutant embryos. Dilated right atria and a complete AVCD with
a single atrioventricular junction were obvious (Figure 2F), while
at this stage septation was complete in the wild-type controlDevelopmental Cell 16, 528–538, April 21, 2009 ª2009 Elsevier Inc. 529
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degeneration was observed in the livers of many of the
SRp38/ embryos (Figures 2G and 2F). These data indicate
that SRp38 is critical for normal cardiac development. TUNEL
assays and immunostaining with phospho-histone-H3 Ser10
antibodies were also performed; however, no evidence of aber-
rant apoptosis or abnormal proliferation was observed in the
mutant hearts at E14.5 (Figure S2).
Cardiac Triadin Expression Is Deregulated in Mice
Lacking SRp38
To identify genes regulated by SRp38 that might be responsible
for the abnormalities in the SRp38/ heart, we first performed
microarray analysis using ventricular RNAs extracted from
SRp38/ and wild-type embryos at E13.5 and E14.5. Given
that SRp38 functions as a general splicing repressor as well as
a sequence-specific activator, we reasoned that loss of SRp38
might have a general effect on gene expression. We therefore
Figure 2. SRp38/ Mice Have Multiple
Heart Defects and Severe Liver Damage
HE staining was performed on heart transverse
sections of SRp38 wild-type (A, C, and E) and
mutant (B, D, and F) embryos to examine cardiac
morphology at E14.5 (A–D) and E16.5 (E and F).
SRp38/ hearts have atrial septal defects (ASD)
and ventricular septal defects (VSD) at E14.5
(compare [A] and [B]). High-power view of the left
ventricle (boxed area) shows disorganized cardio-
myocytes and thin myocardium in the mutant as
compared to the wild-type littermate (C). Atrioven-
tricular canal defect (AVCD, arrow) and enlarged
right atria (RA) are observed in the SRp38/ heart
at E16.5 (compare [E] and [F]).
RV, right ventricle; LV, left ventricle; tv, tricuspid
valve; mv, mitral valve. HE-stained transverse
sections of the liver showed large amounts of
tissue loss in the SRp38/ embryos ([H], arrow-
head, compared to wild-type control [G]).
analyzed an expression array designed
to detect changes in total mRNA levels
(see Experimental Procedures). While
the majority of genes examined were
found to be expressed similarly in
SRp38/ and wild-type ventricles,
a number of differences were observed
(Table S1). Among these were genes en-
coding enzymes involved in energy or
hemoglobin metabolic pathways (see
TableS1, indicatedby * after gene names,
such as mino levulinate synthesis), which
might have been affected by poor func-
tioning of and/or circulation in the mutant
hearts. Changes in other affected genes,
listed in Table S1 and indicated by # after
gene names (such as fibulin5 and elastin),
may reflect the underdeveloped myocar-
dium (i.e., thin and nonlaminated; see
Figure 2D) observed in the mutant hearts,
rather than direct effects of SRp38 loss. RT-PCR analysis of the
downregulated transcripts showed no accumulation of alterna-
tive or aberrantly spliced RNAs (Figure S3), and none of these
transcripts contain consensusSRp38binding sites.Weconclude
that depletion of SRp38 did not invoke widespread defects in
gene expression in cardiomyocytes. Similar observations were
made previously with heart-specific ablation of SC35 (Ding
et al., 2004) and ASF/SF2 (Xu et al., 2005).
The above transcripts seem unlikely to have been directly
affected by the loss of SRp38; rather, the expression changes
observed likely reflect the poor functioning of the mutant hearts.
Especially intriguing, however, were differences in accumulation
of mRNAs encoding distinct isoforms of the cardiac protein tria-
din. Triadin pre-mRNA has previously been shown to generate
distinct mRNA isoforms by alternative splicing (Hong et al.,
2001; also see Figure 3A). The major protein isoform, triadin 1,
has been shown to play an important role in Ca2+ handling during
EC coupling (Kirchhefer et al., 2001; Terentyev et al., 2005).530 Developmental Cell 16, 528–538, April 21, 2009 ª2009 Elsevier Inc.
Developmental Cell
SRp38 Is Required for Proper Heart DevelopmentFigure 3. Altered Triadin Pre-mRNA
Splicing Patterns and Significantly Reduced
Triadin and CSQ2 Protein Levels Are
Observed in the SRp38/ Hearts
(A) Triadin gene expression is regulated by alterna-
tive RNA splicing. Exons 1–8 are shared by all
three isoforms, while exon 9, exon 10, and exon
11 are specific to triadin 1, triadin 2, and triadin 3
mRNAs, respectively. Note that exons and introns
are not shown to scale. Primers used for real-time
RT-PCR analysis were also indicated. (The
forward primer was designed to span the junction
of exons 7–8 in order to detect only spliced prod-
ucts.)
(B) Comparison of the levels of triadin transcript in
SRp38/ and SRp38+/+ hearts at E13.5 and
E14.5. Ventricular RNA was extracted from
SRp38/ and SRp38+/+ embryonic hearts and
used for real-time RT-PCR analysis. Experiments
were repeated at least three times; relative
amounts of transcripts after normalization with
beta-actin mRNA levels were plotted as mean ±
SD for each sample.
(C) Total triadinmRNA levels (triadin 1plus triadin 2)
were reduced inSRp38/hearts. Real-timeRT-PCRwasperformedusingprimers targetedagainst constitutively spliced exonsof triadin pre-mRNAandanalyzed
as described in (B).
(D) CSQ2 mRNA levels in SRp38/ and SRp38+/+ hearts. Real-time RT-PCR was performed and analyzed as described in (B).
(E) Decreased levels of triadin and CSQ2 proteins in the SRp38/ heart. Ventricle extracts were prepared from E14.5 embryos, resolved by SDS-PAGE, and
analyzed with indicated antibodies.To confirm the difference in triadin mRNA accumulation
suggested by the microarray analysis, we performed real-time
RT-PCR with the ventricular RNAs to quantitate levels of triadin
mRNA isoforms. Consistent with the microarray data, a signifi-
cant decrease in triadin 1 and an increase in triadin 2 mRNA
levels was observed in the E13.5 SRp38/ heart (Figure 3B,
compare lanes 1 with 2, and 5 with 6), suggesting that SRp38
promotes accumulation of triadin 1 over triadin 2 mRNA. We
also detected an increase in a third isoform, triadin 3, although
the level was low (data not shown). At E14.5, triadin 1 and triadin
2 mRNA levels in the mutant heart did not change significantly
relative to expression levels at E13.5 (Figure 3B, compare lanes
1 and 3, 5 and 7). In contrast, in the wild-type heart, triadin 1
mRNA levels at E14.5 were significantly increased relative to
levels at E13.5 (compare lanes 2 and 4). Triadin 1 mRNA levels
at E14.5 were 4- to 5-fold higher in wild-type compared to
mutant hearts (compare lanes 3 and 4), while levels of triadin
2 mRNA were comparable (lanes 7 and 8). Aberrantly spliced
triadin transcripts were not detected (Figure S4A). In summary,
the ratio of triadin 1 to triadin 2 mRNA was significantly reduced
in SRp38 mutant hearts at both E13.5 and E14.5 (Figure S4B), as
were total triadin mRNA levels (Figure 3C).
To investigate whether the changes in triadin mRNA we
observed were specific, we examined by real-time RT-PCR the
levels of transcripts encoding other sarcoplasmic reticulum
membrane-related proteins in the E13.5 and E14.5 mutant and
wild-type ventricles. With one exception, all transcripts tested,
which included those encoding the ryanodine receptors
(RyR2), junctin, SERCA 2a, and PLB (Figure S5 and data not
shown), were unchanged between wild-type and mutant hearts.
However, CSQ2 mRNA levels were slightly decreased in the
mutant at E13.5 and were significantly reduced at E14.5
(Figure 3D, lanes 1–4).DeveWe next wished to determine whether the changes in triadin
and CSQ2 mRNA levels were reflected at the protein level. To
this end, protein extracts were prepared from E14.5 ventricles
and used for western blot analysis (Figure 3E). The triadin anti-
body used was capable of detecting both triadin 1 and triadin 2
isoforms (see Experimental Procedures). Consistent with the
real-time RT-PCR data, a striking decrease in total triadin protein
levels was observed in the mutant ventricles, and CSQ2 protein
levels were also greatly reduced. As expected, SRp38 was not
detected in the mutant hearts. Levels of SERCA 2a were
unchanged between wild-type and mutant hearts.
SRp38 Specifically Binds to Triadin-1-Specific Exon 9
RNA In Vitro
The above data suggest that SRp38 regulates expression of
triadin and/or CSQ2 in developing cardiomyocytes. Because
the change in mRNA expression of triadin isoforms was
observed earlier than the decreased CSQ2 mRNA levels, and
because the changes in triadin mRNAs were consistent with
a defect in alternative splicing, we examined in more detail
possible regulation of triadin pre-mRNA splicing by SRp38.
The triadin gene contains 11 exons; alternative splicing leads
to three isoforms that differ only in which of the last three exons
is included or excluded in the mature RNA. In triadin 1, exon 9
(E9) is included; in triadin 2, exon 10 (E10) is included; and in
triadin 3, exon 11 (E11) is included (Hong et al., 2001).
We first examined the sequences of the three exons for the
presence of potential SRp38 binding sites. Strikingly, we found
two purine-rich motifs, separated by nine nucleotides, in triadin
1-specific E9; each constitutes an excellent match to the
SRp38 consensus sequence (AAAGACAAA) (Figures 4A and
4B; Shin and Manley, 2002). Neither E10 nor E11 contained
a match to the SRp38 consensus sequence (data not shown).lopmental Cell 16, 528–538, April 21, 2009 ª2009 Elsevier Inc. 531
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Triadin-1-Specific Exon 9 RNA
(A) Schematic diagram of triadin constitutive exon
8 (E8) and 50 alternative exon 9 (E9), and auxiliary
sequences. Filled boxes denote two putative
SRp38 binding sites identified in E9. SS, splice
site; ASS, alternative splice site.
(B) Comparison of the two putative SRp38 binding
sites within E9with the selected SRp38 consensus
sequence.
(C) SRp38 binds to triadin 1-specific E9 RNA but
not to triadin 2-specific E10 RNA. In vitro tran-
scribed triadin 1-specific E9 or triadin 2-specific
E10 RNA was used in a gel shift assay with
increasing amounts of GST-tagged SRp38 RBD
as indicated.
(D) SRp38 only weakly binds to E9 mutant RNA.
Two SRp38 binding sites were replaced with the
indicated nucleotides in E9 RNA. Gel shift assays
were performed as in (C).
(E) Competition assay with 32P-labeled E9 RNA
and increasing amounts of unlabeled RNAs as
competitors. Gel shift assays were performed as
in (C). Each competitor was used at 2- or 6-fold
molar excess over the probe. RNA-protein
complex was indicated by arrows.To determine whether SRp38 binds E9 specifically, we prepared
32P-labeled E9 RNA containing the putative SRp38 binding sites
(60 nucleotides in length) and compared binding in gel shift
assays with E10 RNA (prepared in a similar fashion) (Figure 4C).
The SRp38 derivative used contains only the RBD but displays
the same RNA binding specificity as the full-length GST-SRp38
protein (data not shown). The results indicate that SRp38 indeed
binds to E9 RNA in a concentration-dependent manner (lanes 1–
4) but not detectably to E10 RNA (lanes 5–8). SRp38 bound to E9
RNA with an affinity comparable to its affinity for the GluR-B flop
exon (Feng et al., 2008; Figure S6A). In addition, two other SR
proteins, ASF/SF2 and SC35, did not display significant affinity
for E9 RNA (Figure S6B).
We next wished to confirm that the putative SRp38 binding
sites in E9 were responsible for the observed SRp38 binding.
To this end, gel shift assays were performed with an E9-RNA in
which the two motifs were mutated (Figure 4A; see also Experi-
mental Procedures). SRp38 bound the mutant RNA very weakly,
as compared to the binding to wild-type E9 RNA (Figure 4D,
compare lanes 2 and 3). We also performed a competition assay
with increasing amounts of unlabelled RNAs as competitors.
As shown in Figure 4E, the mutant RNA was ineffective as
a competitor while the wild-type RNA eliminated binding
(compare lanes 2 and 3 with 4 and 5). Together, these data indi-
cate that SRp38 specifically binds to the E9 RNA and that
binding is dependent on SRp38 binding sites in the RNA.
SRp38 Activates Splicing In Vitro
of Pre-mRNA Containing Triadin Exon 9
in a Sequence-Dependent Manner
We next asked if SRp38 could activate splicing of an E9-contain-
ing substrate. To this end, we utilized a strategy we established532 Developmental Cell 16, 528–538, April 21, 2009 ª2009 Elsevierpreviously to measure SRp38-dependent splicing activation
(Feng et al., 2008). Specifically, we constructed chimeric
b-globin RNA substrates in which triadin E9 containing the
SRp38 binding motif (wild-type or mutant) and E10 were used
to replace sequences in the downstream b-globin exon (b-E9,
b-E9 mutant, and b-E10; see Feng et al., 2008 and Experimental
Procedures). Splicing of these RNAs was assayed either in
complete HeLa nuclear extract (NE) or in a splicing-competent
extract lacking all SR proteins including SRp38 (S100 + NF 40-
60; see Feng et al., 2008 and Experimental Procedures) plus
purified GST-SRp38 (Figure 5A). Significantly, the b-E9 RNA
was efficiently spliced in a SRp38-dependent manner (lanes
1–4). Splicing of the b-E9 mutant and b-E10 substrates, on the
other hand, was not activated at all by SRp38 (lanes 5–8 and
9–12, respectively. Note that splicing of the b-E10 RNA was
stalled after the first step, even in NE, reflecting the activity
of second-step inhibitory element in E10 [Y.F. and J.L.M.,
unpublished data].) To provide additional evidence that
SRp38-dependent splicing was due to SRp38 binding to the
E9 RNA, we performed competition assays with increasing
amounts of nonlabeled RNAs. Splicing of the b-E9 was
completely inhibited by a 9-fold molar excess of the wild-type
E9 RNA (Figure 5B, lane 3), while the same amount of the mutant
RNA showed at most only a slight inhibition (Figure 5B, lanes
4 and 5).
SRp38 Promotes Inclusion of Exon 9 in Triadin
Pre-mRNA Splicing in DT40 Cells
We next wished to ask whether SRp38 favors inclusion of exon
9 in triadin pre-mRNA splicing in an in vivo setting. To this end,
we constructed a triadin minigene plasmid in which a truncated
triadin cassette containing exons 8–11 was preceded by theInc.
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(Figure 6A). This plasmid was stably transfected into chicken
DT40 cells with the genetic background SRp38+/+ or SRp38/.
Stably transfected colonies were isolated, and total RNAs were
extracted and analyzed first by RT-PCR in the presence of
32P UTP. As shown in Figure 6B, while triadin 2 mRNA levels
were comparable in the two cell types, there was significantly
less of the triadin 1 variant in the SRp38/ cells, suggesting
Figure 5. SRp38 Specifically Activates
Splicing of a Substrate Containing Triadin-
1-Specific Exon 9 RNA
(A) SRp38 activates splicing of a substrate con-
taining triadin 1-specific E9. In vitro splicing was
performed in HeLa S100 extract using E9, E9
mutant, or E10 containing substrates (b-E9, b-E9
mutant, or b-E10) with indicated additions.
SRp38 splicing activity in S100 requires a nuclear
fraction (NF40-60) prepared by ammonium sulfate
precipitation.
(B) Splicing of b-E9 in vitro in the presence of
unlabelled competitors. Competitors were used
at 3- or 9-fold molar excess over the pre-mRNA.
that SRp38 promotes inclusion of tria-
din-1-specific exon 9. Actin mRNA levels
were equivalent in the two cell lines
(Figure 6B). To extend the above results,
we analyzed RNA isolated from five
different colonies derived from each cell
line by real-time RT-PCR and compared
the ratio of triadin 1 to triadin 2 mRNA levels. Consistent with
the above RT-PCR results, a significant difference was observed
between SRp38+/+ and SRp38/ cells, such that there was
a near 5-fold increase in the ratio of triadin 1 to triadin 2 mRNA
in the presence of SRp38 (Figure 6C). Thus, SRp38 is capable
of regulating alternative splicing of triadin pre-mRNA in vivo as
well as in vitro. To provide additional evidence that the effects
on triadin pre-mRNA splicing were specific, we constructedFigure 6. SRp38 Enhances Inclusion of Tria-
din Exon 9 in Stably Transfected DT40 Cells
(A) Diagram of reporter plasmid containing the
indicated triadin genomic sequences, procedure
for stable transfection of the reporter plasmid
into SRp38+/+ and SRp38/ DT40 cell lines, and
the two alternatively spliced triadin products. The
forward primer was designed to span the junction
of exons 7–8 in order to detect only spliced prod-
ucts.
(B) SRp38 depletion decreases the level of triadin
1 mRNA in SRp38/ DT40 cells. RNA was
extracted from SRp38+/+ and SRp38/ cells,
and 32P RT-PCR was performed. RNA was
resolved on a 6% denaturing PAGE, and triadin 1
and triadin 2 products were shown. Actin mRNA
levels were used as a loading control.
(C) The ratio of triadin 1 to triadin 2 mRNA levels is
greatly reduced in SRp38/ DT40 cells. RNA was
extracted from SRp38+/+ and SRp38/ DT40 cell
clones stably expressing the triadin reporter
construct. Real-time RT-PCR analysis was per-
formed as described in Figure 3B. Comparison
was made between five independent SRp38+/+
and five independent SRp38/ DT40 cell clones.
(D) Basal splicing activity in SRp38+/+ and
SRp38/ DT40 cells. A plasmid containing the
human b-globin gene was constructed and stably
transfected into DT40 cells following the same
strategy employed in (A). RNA was extracted and
32P RT-PCR was performed.Developmental Cell 16, 528–538, April 21, 2009 ª2009 Elsevier Inc. 533
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Ca2+ Sparks Is Increased in SRp38/
Myocytes
(A) Confocal images of cardiomyocytes isolated
from embryos at E14.5.
(B) Representative line-scan images of Ca2+
sparks in myocytes incubated in Tyrode’s solution
containing 5 mM Ca2+.
(C) Spark frequency was compared between
SRp38+/+ and SRp38/ cardiomyocytes.
Comparison of distribution of Ca2+ sparks
between SRp38+/+ and SRp38/ cardiomyocytes
was made by plotting number of sparks events
against (D) spark amplitude (DF/F), (E) full duration
at half-maximal amplitude (FDHM; ms), or (F) full
width at half-maximal amplitude (FWHM; mm),
respectively. SparkMaster was used to detect
and analyze spark parameters. Data analysis
was performed on 75 sparks from wild-type prep-
arations and 198 sparks from multiple SRp38/
cardiomyocyte preparations. Quantitative data
were expressed as means ± SE.and analyzed cell lines expressing a human b-globin minigene.
Levels of b-globin mRNA were equivalent between SRp38+/+
and SRp38/ cells (Figure 6D).
Ca2+ Handling Is Affected in Isolated SRp38/
Cardiomyocytes
We next wished to investigate whether the reduced levels of tria-
din and/or CSQ2 might affect Ca2+ homeostasis in SRp38/
embryonic cardiomyocytes. To this end, we developed an
approach using primary cultures of cardiomyocytes isolated
from wild-type and SRp38/ embryos at E14.5. The myocytes
were spherical in appearance immediately after dissociation
and become flattened and spread out after overnight incubation
in culture. Wild-type and mutant cardiomyocytes appeared
morphologically identical (Figure 7A). Western blots indicated
that triadin and CSQ2 levels were, as expected, reduced in the
SRp38/-cultured cardiomyocytes (Figure S7). We measured
intracellular cytosolic Ca2+ in these cells using fluo-4 and laser
scanning confocal microscopy (see Experimental Procedures).
Both the SRp38/ and wild-type myocytes displayed
spontaneous contractile activity and alterations in Flou-4 fluores-
cence. While the pattern and frequency of spontaneous contrac-
tions were variable in isolated myocytes, the amplitude of Ca2+
transients (expressedasanelevation abovediastolic levels; F/Fo)
was not significantly different in the mutant myocytes (data not
shown). Ryanodine (1 uM for 3 min) did not abolish spontaneous
Ca2+ transients but led to a reduction in the amplitude of the Ca2+
transients, and there was not much difference between the two
groups (data not shown). These data support the view that fetal
cardiomyocyte contraction is mainly regulated by Ca2+ influx
from extracellular sources rather than Ca2+ release from the
sarcoplasmic reticulum (Artman et al., 2000).
We next examined whether the properties of Ca2+ sparks,
the elementary Ca2+ release event from the sarcoplasmic reti-
culum (Cheng et al., 1993), might be influenced in SRp38/534 Developmental Cell 16, 528–538, April 21, 2009 ª2009 Elseviermyocytes. To that end, we incubated wild-type and mutant
cardiomyocytes with 5 mM Ca2+ to augment sarcoplasmic
reticulum Ca2+ loading (Seki et al., 2003). Strikingly, 198 spark
events were detected from 50 mutant myocytes isolated from
5 embryos, while only 75 sparks were observed from 51 wild-
type myocytes from 7 embryos (Figure 7B). We then analyzed
the frequency and amplitude of the sparks using SparkMaster
(see Experimental Procedures). As shown in Figure 7C, spark
frequency was significantly increased in the SRp38/myocytes
as compared to the wild-type myocytes. The SRp38/
myocytes also displayed a significantly smaller amplitude (1.72 ±
0.03, n = 198, p < 0.01) compared to the wild-type cells (2.87 ±
0.20, n = 75) (Figure 7D). Additionally, the width of Ca2+ sparks
(FWHM) was altered in the SRp38/ myocytes, decreasing
from 3.24 ± 0.21 mm (n = 75) to 2.48 ± 0.08 mm (n = 198, p <
0.05) (Figure 7E), although no significant differences were de-
tected in the duration of sparks (FDHM) between the two groups
of cells (Figure 7F). The data indicate that there is greater occur-
rence of Ca2+ sparks in the SRp38/ myocytes, reflecting
a specific role of SRp38 in regulating Ca2+ release from the
sarcoplasmic reticulum in embryonic cardiomyocytes.
DISCUSSION
During mouse development, the heart undergoes dramatic
morphological changes and critical modifications in gene
expression. Here, we have provided evidence that the splicing
factor SRp38 is critically involved in cardiac development and
that its loss leads to multiple cardiac defects, changes in triadin
pre-mRNA splicing, and altered intracellular Ca2+ handling in
isolated cardiomyocytes. Below, we discuss how SRp38 func-
tions as an important regulator of alternative splicing during heart
development and how loss of SRp38 leads to changes in triadin
pre-mRNA splicing and altered Ca2+ handling in embryonic
cardiomyocytes.Inc.
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tion of specific SR protein is expected to result in multiple
general defects in RNA metabolism and therefore cell death or
early embryonic lethality. This has been demonstrated by loss
of ASF/SF2 in chicken DT40 cells (Wang et al., 1996) and
gene-targeting deletion of SRp20 (Jumaa et al., 1999) and
SC35 (Wang et al., 2001) in mice. These findings also exemplify
the difficulties in analysis of splicing defects caused by ablation
of SR proteins in vivo. However, by application of conditional
gene-targeting approaches, Fu and colleagues demonstrated
connections between the heart-specific inactivation of ASF/
SF2, defects in several alternative splicing events, and a severe
defect in the function of adult cardiac muscles (Xu et al., 2005).
For example, one of the affected transcripts, the Ca2+/calmod-
ulin-dependent kinase IId (CaMKIId) pre-mRNA, showed a defect
in the postnatal splicing switch in ASF/SF2/ hearts; this defect
results in production of a kinase that is mistargeted to sarco-
lemmal membranes, causing severe EC coupling defects (Xu
et al., 2005). However, it remains to be determined whether the
misregulated CaMKIId pre-mRNA is a direct target of ASF/SF2,
and how ASF/SF2 regulates its splicing. Especially given the
recently identified roles for ASF/SF2 in mRNA export, genomic
instability, and translation (see Introduction), it is possible that
ASF/SF2 affects expression of a factor(s) that in turn modulate(s)
the splicing transition of theCaMKIId pre-mRNA during postnatal
heart remodeling.
In the present study, we provided considerable evidence that
SRp38 directly regulates alternative splicing of cardiac triadin
pre-mRNA. Our initial experiments dealing with SRp38 indicated
that the protein, when dephosphorylated, functions as a general
splicing repressor, without apparent sequence specificity (Shin
andManley, 2002; Shin et al., 2004). Although these experiments
provided no evidence that SRp38 could, like other SR proteins,
function as a splicing activator, they did identify, by SELEX,
a specific high-affinity binding site for SRp38, andwe speculated
that under some conditions SRp38 might indeed be capable
of functioning as a splicing activator. Indeed, Feng et al. (2008)
showed recently that phosphorylated SRp38 is in fact a
sequence-specific activator, both in in vitro and in vivo assays,
and can regulate alternative splicing of the GluR-B pre-mRNA
(Komatsu et al., 1999) in a sequence-specific manner. The
RNA binding and splicing data with triadin pre-mRNA presented
here are essentially identical and indicate that triadin is indeed
a direct SRp38 target. However, triadin exon 9 alternative
splicing may be coupled with altered polyadenylation (see
Figure 3A), which raises the possibility that SRp38 may play a
more complex role in triadin pre-mRNA processing.
In our experiments, we observed reduced triadin 1 mRNA
levels but increased levels of triadin 2 mRNA in the absence
of SRp38. However, the switch in triadin splicing led to a reduc-
tion in total levels of triadin protein, rather than accumulation of
triadin 2. Given that no function has been attributed to triadin
2, it is possible that it is inactive and degraded, at least at this
developmental stage. In addition to these changes, we also
observed downregulation of CSQ2 mRNA and protein expres-
sion but not of other sarcoplasmic reticulum-related proteins.
Related observations have been made when triadin 1 and
CSQ2 levels were altered in transgenic mice: overexpression
of triadin1 was reported to downregulate both RyR2 and junctinDeve(Kirchhefer et al., 2001), while inactivation of CSQ2 essentially
eliminated expression of triadin and junctin (Knollmann et al.,
2006). Together with our data, these findings suggest that triadin
and CSQ2 associate not only with each other but also with other
proteins involved in Ca2+ handling, including RyR2 and junctin.
Changes in expression of any of these proteins may significantly
alter expression of the others, indicating that expression of these
Ca2+ homeostatic proteins is tightly coordinated during cardiac
development.
Consistent with the observed reduction in triadin and CSQ2
protein levels, our data demonstrated that intracellular Ca2+
handling was altered in isolated SRp38/ cardiomyocytes.
Specifically, Ca2+ sparks occurred with greater frequency but
lower amplitude in SRp38/ cardiomyocytes than in wild-type
cells. It is likely that this phenotype is caused by reductions in tri-
adin or CSQ2 alone or in combination with each other. Several
reports have established the importance of triadin 1 in controlling
Ca2+ handling in adult cardiomyocytes, although its precise role
appears complex. For example, adenoviral-mediated overex-
pression of triadin 1 in cultured rat cardiomyocytes led to an
increased frequency of spontaneous Ca2+ sparks, accompanied
by decreased amplitudes (Terentyev et al., 2005), while trans-
genic overexpression of triadin 1 in the mouse was reported to
have almost the opposite effect, increased Ca2+ spark amplitude
but without changes in spark frequency (Kirchhefer et al., 2001).
Results obtained with ablation of CSQ2 (Knollmann et al., 2006)
also indicate that normal Ca2+ release relies on an intricate
balance among the Ca2+ homeostatic proteins, including
RyR2, triadin, CSQ2, and junctin. Due to differences in the sarco-
plasmic reticulum in embryonic versus adult cardiomyocytes
(Itzhaki et al., 2006), it is possible that the Ca2+ handling defects
we observed may involve additional mechanisms than reduced
levels of triadin and/or CSQ2. Re-expressing one or both of
these proteins will be an intriguing topic for future studies that
focus onmechanisms of Ca2+ handling in embryonic cardiomyo-
cytes by RyR2 and regulatory proteins such as triadin.
A number of cardiac-related defects were observed in the
SRp38/ embryos. Several of these have been observed in
many unrelated knockout mice and may reflect general or
secondary effects (Conway et al., 2003). For example, hepatic
necrosis has been observed in many mice with severe cardiac
defects (Shou et al., 1998; Araki et al., 2004), as heart failure
can cause secondary congestive liver disease. Similar liver
damage was present in SRp38/ embryos, which, in combi-
nation with the observed cardiac defects, almost certainly
contributes to the observed embryonic lethality and growth
retardation. The cardiac defects observed in the SRp38/
mice are unlikely related to the changes in expression of triadin
and/or CSQ2, as loss of triadin (Shen et al., 2007) or CSQ2 (Knoll-
mann et al., 2006) has little effect on cardiac development.
Therefore, the various cardiac abnormalities on the one hand
and the triadin splicing defects and concomitant altered Ca2+
handling on the other likely reflect independent effects of
SRp38 inactivation. This suggests that SRp38 plays a broad
role in regulating alternative splicing during cardiac develop-
ment. While future studies will be required to elucidate the
molecular bases for these effects, it is remarkable that the
requirement for SRp38 during embryonic development seems
to be limited to the heart. Given the broad tissue distribution oflopmental Cell 16, 528–538, April 21, 2009 ª2009 Elsevier Inc. 535
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SRp38 plays additional important roles later in development.
In summary, the loss of splicing factor SRp38 leads to multiple
cardiac defects in mice. SRp38 specifically regulates alternative
splicing of triadin pre-mRNA, as loss of SRp38 caused a switch
in the triadin isoform pattern. SRp38 inactivation also diminished
CSQ2 expression and altered intracellular Ca2+ cycling in embry-
onic cardiomyocytes. By understanding how SRp38 modulates
cardiac triadin expression, we have moved closer toward eluci-
dating the role of alternative splicing as a genetic modifier during
heart development.
EXPERIMENTAL PROCEDURES
Construction of the Targeting Vector and Generation of SRp38
Knockout Mice
A 5.5 kb fragment upstream of the SRp38 exon 1 and a 3.5 kb fragment down-
stream of exon 2 were amplified by PCR and sequentially subcloned into the
pPNT targeting vector (Qu et al., 2003). Linearized vector was electroporated
into E14 embryonic stem cells. Southern blotting identified 20 out of 200 G418
and gancyclovir double-resistant clones that had undergone homologous
recombination. Two ES clones were injected into C57BL/6 blastocysts. Six
chimeric male mice with >90% ES cell contribution to coat color were bred
with C57BL/6 females to produce F1 heterozygotes, which were interbred to
produce F2 progeny. A genomic PCR assay to detect the wild-type allele
(330 bp) or the mutant SRp38 allele (240 bp) was designed using a common
intron primer (50 GCTGGAATGGTGTCAGCACAGCG 30) and the SRp38 wild-
type exon2 primer (50 TCCAAGAATCATATCCAGTGGCT 30) or the neoR
gene primer (50 CTACCCGGTAGAATTGACCTGCA 30).
Histological Analysis
Embryos generated by timed matings were isolated, fixed in 10% buffered
formalin, and then embedded in paraffin and sectioned. The sections were
stained with hematoxylin and eosin (HE) and analyzed by microscopy. Freshly
dissected whole embryos were also observed and photographed using a dis-
secting microscope.
Microarray Analysis and Real-Time RT-PCR and 32P RT-PCR
Ventricle total RNA extracted at E13.5 and E14.5 was used for microarray
analysis. In brief, double-stranded cDNA was synthesized from 10 mg of total
Trizol-extracted RNA by using the Microarray cDNA Synthesis Kit (Roche).
In vitro transcription using double-stranded cDNA as a template in the pre-
sence of biotinylated UTP and CTP was carried out using an ENZO BioArray
HighYield RNA Transcript Labeling Kit (ENZO Biochem). Biotin-labeled
cRNA was purified, fragmented, and used for hybridization on a Mouse
Genome 430A 2.0 Array (Affymetrix) in the Columbia University Cancer Center
microarray core facility. Data were analyzed with the Affymetrix GeneChip
Expression Analysis Software.
Real-time RT-PCR reactions were carried out with total RNA extracted
from the ventricle at the indicated stages. RT reactions were performed using
the Transcriptor Reverse Transcriptase (Roche), and real-time PCR was
performed using the SYBR Green PCR Master Mix (Applied Biosystems) and
performed on Applied Biosystems 7300 Real Time PCRmachine permanufac-
turer instructions. PCR results were quantified using ABI software (SDS); delta
Rn valueswere exported to and analyzed usingMicrosoft Excel. Gene-specific
primer sets (50-30) include: for triadin 1, triadin-F (GATGATGGCAAAAGAGGAC
AA) and triadin-R1 (GGAGAAAGTGAAACCAACAGC); for triadin 2, triadin-F
(GATGATGGCAAAAGAGGACAA) and triadin-R2 (TTAAATCCCCATGGACAA
ACA); for triadin 3, triadin-F (GATGATGGCAAAAGAGGACAA) and triadin-R3
(TGTGGGAGAAAACACCACAA); for total triadin mRNA levels, triadin-F (GATG
ATGGCAAAAGAGGACAA) and triadin-R (TGCACAGCTGGCATCTCTT); for
calsequestrin2 (CSQ2), CSQ2-F (TCAAAGACCCACCCTACGTC) and CSQ2-R
(GGGTCAATCCACAAGATGCT); for Junctin, Junctin-F (GCAGGAGGATA
GAGGGAAGG) and Junctin-R (TTCCTCGCCTGTCTTTGTCT); for cardiac rya-
nodine receptor (RyR2), RyR2-F (AGCCCTCACGACTAAAGCAA) and RyR2-R
(CCACCCAGACATTAGCTGGT); for SERCA-2a, SERCA-2a-F (AAGC536 Developmental Cell 16, 528–538, April 21, 2009 ª2009 Elsevier ITATGGGAGTGGTGGTG) and SERCA-2a-R (GCAATGCAAATGAGGGAGAT);
for phospholamban (Pln), Pln-F (TACCTCACTCGCTCGGCTAT) and Pln-R
(GATGCAGATCAGCAGCAGAC); for beta-actin, actin-F: ATGAGCTGCCTGA
CGGCCAGGTCATC and actin-R: TGGTACCACCAGACAGCACTGTGTTG.
PCR utilizing [a 32p] UTP was performed according a protocol previously
described (Kashima et al., 2007).
Western Blotting
For western blotting analysis, frozen mouse ventricles were homogenized and
lysed as described (Li and Minden, 2003). Samples were collected, resolved
on an SDS-PAGE, and analyzed using indicated antibodies. Primary anti-
bodies employed include mouse anti-tubulin (Hybridoma bank), anti-CSQ2
(Affinity Bioreagents), mouse anti-triadin and anti-SERCA2a (Santa Cruz),
and lab-made rabbit anti-SRp38 (Shin and Manley, 2002).
Plasmid Constructions, Gel Shift Assay, In Vitro Splicing,
Cell Culture, and Transfection
Plasmids (b-E9 and b-E10) used to produce substrates for in vitro splicingwere
constructed by replacement of sequences between AccI site andBamHI site in
the second exon with the indicated sequences. The b-E9 mutant was
produced by subcloning two mutant oligos containing nucleotides
(GGTCTGTCC..TTTCTGTTT) in place of two SRp38 putative binding sites
(GGAGACAGC..AAAGAGAAT). The forward primer was GGTCTGTCCAGGAG
GTCCT TTCTGTTTAATGGGCAAGAAGCAGATGCAGTCAACTGAAAA, and
the reverse primer was TTTTCAGTTGACTGCATCTGCTTCTTGCCCATTAAAC
AGAAAGGACCTCCTGGA CAGACC. For in vitro gel shift assays, we con-
structed plasmids by inserting the indicated sequences into pBluescript
SK(+) plasmid. Gel shift assays and in vitro splicing were performed as previ-
ously described (Feng et al., 2008). The triadin truncated reporter minigene
was constructed as described previously (Feng et al., 2008). DT40 cells of
different backgrounds including wild-type or SRp38/ were maintained
essentially as described previously (Shin et al., 2004). Transfection of the
triadin truncated reporter minigene into DT40 cells was also performed as
described previously (Feng et al., 2008).
Isolation of Embryonic Cardiomyocytes and Primary Cell Culture
Embryos were removed from pregnant female mice at 14.5 days. Cardiac
myocytes were isolated from embryonic hearts as previously described (An
et al., 1996; Liu et al., 1999) with slight modifications. In brief, the dissected
ventricles were incubated in Ca2+-free isolation buffer (in mM: 116 NaCl,
20 HEPES, 1.0 NaH2PO4, 5.5 Glucose, 5 KCl, and 0.8 MgSO4 [pH 7.35]) con-
taining 0.4 mg/mL collagenase type II (Worthington) for 40 min at 37C and
then rinsed with the same buffer without enzyme. The ventricles were dissoci-
ated by pipetting up and down several times, and the isolated cells were
placed on collagen-coated glass coverslips and incubated in DMEM (GIBCO)
plus 10% FBS and 10 mg/mL gentamicin at 37C for 18 to 24 hr before
recording.
Confocal Imaging of Ca2+ Transients and Ca2+ Sparks
in Embryonic Ventricular Myocytes
Ventricular myocytes were incubated with fluo-4 AM (5 mM; Molecular Probes)
for 10 min. Cells were subsequently washed in Tyrode’s solution containing
(in mM): 137 NaCl, 4 KCl, 1 MgCl2, 1.2 NaH2 PO4, 1.8 CaCl2, 10 glucose,
and 10 HEPES (pH 7.4) for 20 min to allow de-esterification. Confocal fluores-
cence imaging was performed with a confocal scanning laser microcopy
(Zeiss 510). The line scanmodewas used for quantitative analysis of Ca2+ tran-
sients and Ca2+ sparks. Confocal imaging of Ca2+ transients was performed
with the myocytes in Tyrode’s solution containing 1.8 mM Ca2+, while Ca2+
sparks were recorded using 5 mM extracellular Ca2+ (Seki et al., 2003). Ca2+
sparks were detected and analyzed using SparkMaster (Picht et al., 2007).
Analysis included spark frequency (sparks 3 s1 3 (100 mm)1), amplitude
(DF/F), full duration at half-maximal amplitude (FDHM; ms), and full width at
half-maximal amplitude (FWHM; mm).
Statistics
Quantitative data were expressed as means ± SE. The paired or unpaired
Student’s t test was applied, and significance was defined at p < 0.05.nc.
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